Brodsky & Smith investigates Arcosa, Fathom, Nuvalent, and Dana boards over merger deals

GlobeNewswire··Read original
2▲0 ▼0Impact / 5
Summary · why it matters

Brodsky & Smith is investigating the boards of Arcosa, Fathom Holdings, Nuvalent, and Dana Incorporated over potential fiduciary duty breaches in their respective merger agreements. Arcosa is being acquired by CRH for $150.00 per share in cash, with a total enterprise value of approximately $8.5 billion. Fathom Holdings is being acquired by Bed Bath & Beyond in a deal implying an equity value of about $53.38 million, with an exchange ratio of 0.2236 Bed Bath & Beyond shares per Fathom share. Nuvalent is being acquired by GSK for $124.00 per share in cash in a deal valued at $10.6 billion. Dana is being acquired by Eaton Corporation in a transaction valued at approximately $5.1 billion, where Eaton shareholders will own at least 50.1% and Dana shareholders approximately 49.9% of the combined company, and Eaton will receive a cash distribution of about $1.1 billion.

Impact on assets 8

Energy Transition & Power Demand▲ · 2 stocks
Arcosa Inc
ACA
± MixedRegulationrelevance

Board investigated over fiduciary duty in merger with CRH; outcome uncertain.

Biotech & Genomic Medicine▲ · 2 stocks
Nuvalent Inc
NUVL
± MixedRegulationrelevance

Board investigated over fiduciary duty in merger with GSK; outcome uncertain.

Electrification & Mobility▲ · 1 stocks
Dana Inc
DAN
± MixedRegulationrelevance

Board investigated over fiduciary duty in merger with Eaton; outcome uncertain.

Real Estate▲ · 1 stocks
Fathom Holdings Inc
FTHM
± MixedRegulationrelevance

Board investigated over fiduciary duty in merger with Bed Bath & Beyond; outcome uncertain.

Consumer Discretionary▲ · 1 stocks
Materials▲ · 1 stocks
© 2026 MarketIVNews